Spectrum of Mutations in Biopsy-Proven CADASIL: Implications for Diagnostic Strategies
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults. Mutations are typically located within epidermal growth factor-like repeat domains in the extracellular part of the Notch3 receptor. Identification of the mutation is critical for genetic counseling and testing of relatives at risk. OBJECTIVES: To identify the spectrum of NOTCH3 mutations in CADASIL and to discuss the implications for diagnostic strategies. DESIGN: Screening for NOTCH3 mutations was performed in 125 unrelated German CADASIL patients with biopsy-proven disease by direct sequencing of exons coding for epidermal growth factor-like repeats. Results were compared with those of previously published studies. RESULTS: We detected 54 distinct mutations (117 missense mutations and 3 in-frame deletions) in 120 (96.0%) of the 125 patients. Of the mutations, 58.3% were located in exon 4 and 85.8% in exons 2 through 6. In 5 patients (4.0%), no mutation was identified. CONCLUSIONS: Almost 90% of mutations could be detected within a few exons (exons 2-6). Thus, genetic testing should initially be focused on these exons, with some variation depending on the population in whom it is being performed. Yet, genetic testing for CADASIL is associated with a nameable proportion of false-negative results. Cases with a high index of clinical suspicion should be investigated by skin biopsy if genetic testing is negative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients
Joutel, A., Vahedi, K., Corpechot, C., Troesch, A., Chabriat, H., Vayssière, C., Cruaud, C., Maciazek, J., Weissenbach, J., Bousser, M.-G., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08083-5 · Cited by 682
MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL
O’Sullivan, M., Jarosz, J. M., Martin, R. J., Deasy, N., Powell, J. F., & Markus, H. S. (2001) · Neurology · doi:10.1212/wnl.56.5.628 · Cited by 363 · cited 2×
“CADASIL may be suspected based on the clinical syndrome, a positive family history, and a typical cranial magnetic resonance image with T2-weighted hyperintense signals in the temporopolar white matter or the external capsule.(3) Final proof, however, requires genetic testing or pathological examination of skin biopsy…”
BackgroundDiagnostic strategies in CADASIL
Markus, H. S., Martin, R. J., Simpson, M. A., Dong, Y. B., Ali, N., Crosby, A. H., & Powell, J. F. (2002) · Neurology · doi:10.1212/wnl.59.8.1134 · Cited by 335 · cited 3×
“However, the criteria for selecting patients and screening protocols largely varied between studies, and in none of them had the diagnosis been systematically confirmed by biopsy.(4,8,9) Thus, it is difficult to draw a conclusion about the sensitivity of genetic testing for CADASIL.”
BackgroundMethodResultSkin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis
Joutel, A., Favrole, P., Labauge, P., Chabriat, H., Lescoat, C., Andreux, F., Domenga, V., Cécillon, M., Vahedi, K., Ducros, A., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07142-2 · Cited by 252
A novel Notch3 gene mutation not involving a cysteine residue in an Italian family with CADASIL
Mazzei, R., Conforti, F. L., Lanza, P. L., Sprovieri, T., Lupo, M. R., Gallo, O., Patitucci, A., Magariello, A., Caracciolo, M., Gabriele, A. L., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000133399.37716.84 · Cited by 48
Cited by
Stroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952
“Most of these are missense mutations altering the number of cysteine residues expressed in an extracellular receptor domain.(191) Although Notch3 is widely expressed in the body and plays an important role in development, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy only a…”
BackgroundChabriat, H., Joutel, A., Dichgans, M., Tournier-Lasserve, E., & Bousser, M.-G. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70127-9 · Cited by 1,088
Self-citationDichgans, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70028-5 · Cited by 397
Self-citationJoutel, A., Monet-Leprêtre, M., Gosele, C., Baron-Menguy, C., Hammes, A., Schmidt, S., Lemaire-Carrette, B., Domenga, V., Schedl, A., Lacombe, P., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39733 · Cited by 379
Duering, M., Zieren, N., Hervé, D., Jouvent, E., Reyes, S., Peters, N., Pachai, C., Opherk, C., Chabriat, H., & Dichgans, M. (2011) · Brain · doi:10.1093/brain/awr169 · Cited by 200
“In all subjects, the diagnosis had been confirmed either by skin biopsy or genetic testing (Joutel et al., 1997; Peters et al., 2005).”
BackgroundSelf-citation
Metadata
- Authors
- Peters, N., Opherk, C., Bergmann, T., Castro, M., Herzog, J., & Dichgans, M.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-01
- Volume
- 62
- Issue
- 7
- Pages
- 1091
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2126703985
- Cited by
- 161
- References
- 5
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spectrum of Mutations in Biopsy-Proven CADASIL: Implications for Diagnostic Strategies. https://app.cochat.ai/papers/10.1001/archneur.62.7.1091
- The paper
- Peters, N., Opherk, C., Bergmann, T., Castro, M., Herzog, J., & Dichgans, M. (2005). Spectrum of Mutations in Biopsy-Proven CADASIL: Implications for Diagnostic Strategies. Archives of Neurology. https://doi.org/10.1001/archneur.62.7.1091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.